Une étude visant à évaluer l'efficacité et l'innocuité du crizanlizumab (5 mg/kg) par rapport au placebo chez des patients adolescents et adultes drépanocytaires qui connaissent des crises vaso-occlusives fréquentes (SPARKLE) (SPARKLE)
Une étude de phase III, multicentrique, randomisée, contrôlée par placebo, en double aveugle, pour évaluer l'efficacité et l'innocuité du crizanlizumab (5 mg/kg) par rapport au placebo, avec ou sans traitement par hydroxyurée/hydroxycarbamide, chez des patients adolescents et adultes drépanocytaires atteints de vaso fréquent -Crises occlusives
A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Study CSEG101A2303 (SPARKLE) is a Phase III, multicenter, randomized, double-blind study to assess efficacy and safety of crizanlizumab 5 mg/kg versus placebo, with or without hydroxyurea/ hydroxycarbamide therapy (HU/HC), in Sickle Cell Disease patients aged 12 years and older with frequent vaso-occlusive crises (4-12 events in 12 months prior to the screening visit).
Participants will be randomized in a 2:1 ratio to the crizanlizumab 5 mg/kg or placebo treatment arm. Central randomization will be stratified by concomitant HU/HC usage (yes/no) and region (South America, North America, and sub-Saharan Africa) at baseline.
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Accès étendu
Contacts et emplacements
Coordonnées de l'étude
- Nom: Novartis Pharmaceuticals
- Numéro de téléphone: 1-888-669-6682
- E-mail: novartis.email@novartis.com
Sauvegarde des contacts de l'étude
- Nom: Novartis Pharmaceuticals
- Numéro de téléphone: +41613241111
Lieux d'étude
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brésil, 41253-190
- Recrutement
- Novartis Investigative Site
-
-
Maranhão
-
São Luís, Maranhão, Brésil, 65020-070
- Recrutement
- Novartis Investigative Site
-
-
São Paulo
-
Campinas, São Paulo, Brésil, 13083-970
- Recrutement
- Novartis Investigative Site
-
Ribeirão Preto, São Paulo, Brésil, 14048-900
- Recrutement
- Novartis Investigative Site
-
Sao Jose Rio Preto, São Paulo, Brésil, 15090-000
- Recrutement
- Novartis Investigative Site
-
São Paulo, São Paulo, Brésil, 08270-070
- Recrutement
- Novartis Investigative Site
-
São Paulo, São Paulo, Brésil, 01232-010
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Montería, Colombie, 230001
- Recrutement
- Novartis Investigative Site
-
-
Antioquia
-
Medellín, Antioquia, Colombie, 050001
- Recrutement
- Novartis Investigative Site
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colombie, 760046
- Recrutement
- Novartis Investigative Site
-
Cali, Valle del Cauca Department, Colombie, 760032
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Eldoret, Kenya, 30100
- Recrutement
- Novartis Investigative Site
-
Kisumu, Kenya, 40100
- Recrutement
- Novartis Investigative Site
-
Kisumu, Kenya, 40103
- Recrutement
- Novartis Investigative Site
-
Siaya, Kenya, 40600
- Recrutement
- Novartis Investigative Site
-
-
Kisumu County
-
Ahero, Kisumu County, Kenya, 40100
- Recrutement
- Novartis Investigative Site
-
-
-
-
-
Kampala, Ouganda, 101
- Recrutement
- Novartis Investigative Site
-
Masaka, Ouganda, 001
- Recrutement
- Novartis Investigative Site
-
Tororo, Ouganda, 10102
- Recrutement
- Novartis Investigative Site
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35233
- Recrutement
- University Of Alabama
-
Chercheur principal:
- Chibuzo Churchill Ilonze
-
Contact:
- Jeanine Dumas
- Numéro de téléphone: +1 205 638 9285
- E-mail: jdumas@uabmc.edu
-
-
California
-
Orange, California, États-Unis, 92868
- Recrutement
- Ctr for Inherited Blood Disorders
-
Contact:
- Emily Lopez
- E-mail: elopez@cibd-ca.org
-
Chercheur principal:
- Vanessa Salinas
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20010
- Recrutement
- Childrens National Hospital
-
Chercheur principal:
- Andrew Campbell
-
Contact:
- Taylor Quinn
- Numéro de téléphone: +1 202 476 5000
- E-mail: tquinn@childrensnational.org
-
-
Florida
-
Jacksonville, Florida, États-Unis, 32209
- Recrutement
- University of Florida
-
Chercheur principal:
- Gabriela Bastidas
-
Contact:
- Tatiana Elias-Grajeda
- E-mail: tatiana.elias-grajeda@jax.ufl.edu
-
-
Georgia
-
Augusta, Georgia, États-Unis, 30912
- Recrutement
- Augusta University Georgia
-
Chercheur principal:
- Girindra Raval
-
Contact:
- Latanya Bowman
- Numéro de téléphone: +1 706 721 2941
- E-mail: lbowman@augusta.edu
-
Riverdale, Georgia, États-Unis, 30274
- Recrutement
- WCG Sonar Clinical Research
-
Chercheur principal:
- Anthony Onyegbula
-
Contact:
- Ify Anierobi
- E-mail: ianierobi@sonarcr.com
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60612
- Recrutement
- Uni of Illinois Hospital and HSC
-
Contact:
- Taif Hassan
- E-mail: tohassan@uic.edu
-
Chercheur principal:
- Santosh Saraf
-
-
Kentucky
-
Louisville, Kentucky, États-Unis, 40202
- Recrutement
- Norton Children s Hospital
-
Chercheur principal:
- Ashok Raj
-
Contact:
- Meagan Despain
- E-mail: meagan.despain@louisville.edu
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21205
- Recrutement
- The Johns Hopkins University School of Medicine
-
Chercheur principal:
- Lydia Pecker
-
Contact:
- Goodness Che
- Numéro de téléphone: +1 410 955 2812
- E-mail: anchang1@jhmi.edu
-
-
Mississippi
-
Flowood, Mississippi, États-Unis, 39232
- Recrutement
- Southern Specialty Research
-
Chercheur principal:
- Sharon Pennington
-
Contact:
- Wendy Thomson
- E-mail: wendy.thomson@southernspecialty.org
-
-
New York
-
The Bronx, New York, États-Unis, 10467
- Recrutement
- Childrens Hospital at Montefiore
-
Chercheur principal:
- Kaitlin Strumph
-
Contact:
- Karen Ireland
- Numéro de téléphone: +1 718 741 2384
- E-mail: kireland@montefiore.org
-
-
North Carolina
-
Greenville, North Carolina, États-Unis, 27834
- Recrutement
- East Carolina University
-
Chercheur principal:
- Beng Fuh
-
Contact:
- Tori Donadio
- E-mail: donadiov21@ecu.edu
-
Winston-Salem, North Carolina, États-Unis, 27157
- Recrutement
- Wake Forest University Baptist Medical Center
-
Contact:
- Julie Fountain
- E-mail: julie.fountain@advocatehealth.org
-
Chercheur principal:
- Alex George
-
-
Pennsylvania
-
Easton, Pennsylvania, États-Unis, 18045
- Recrutement
- Spoknwrdclinicaltrials
-
Chercheur principal:
- Hayman Salib
-
Contact:
- Anne Murunga
- E-mail: amurunga@spoknwrdclinicaltrials.com
-
Philadelphia, Pennsylvania, États-Unis, 19107
- Recrutement
- Thomas Jefferson University Me
-
Contact:
- Katie McDonnell
- E-mail: Katie.McDonnell@jefferson.edu
-
Chercheur principal:
- Sanaa Rizk
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Recrutement
- U of TX Health Science Ct
-
Chercheur principal:
- Modupe Idowu
-
Contact:
- Eyuel Baherey
- E-mail: Eyuel.L.Baherey@uth.tmc.edu
-
Houston, Texas, États-Unis, 77030
- Recrutement
- Texas Childrens Cancer and Hematology Center
-
Chercheur principal:
- Venee Tubman
-
Contact:
- Bogdan Dinu
- Numéro de téléphone: +1 832 824 1000
- E-mail: brdinu@texaschildrens.org
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Key Inclusion Criteria:
- Participants must be aged 12 years and older on the day of signing informed consent. Adolescents include participants aged 12 to <18 years old and adults include participants aged 18 years and older.
- Confirmed diagnosis of SCD by Hb electrophoresis or high-performance liquid chromatography (HPLC) (performed locally or by central laboratory if not available locally). All SCD genotypes are eligible.
- Experienced 4 to 12 VOCs (refer to Section 8.3.1 for study definition of VOC) that are HCP-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) within the 12 months prior to the screening visit. Baseline VOCs are determined by medical history and are required to be documented at source.
- If the participant is on HU/HC, they must be taking it for at least 6 months and at stable dose for at least 3 months prior to the Screening visit and plan to continue taking it at the same dose and schedule until at least the participant has reached 52 weeks of the planned study treatment. Participants who have initiated HU/HC 6-12 months prior to the screening visit must have evidence of insufficient control of acute pain despite initiation. These participants must have a cumulative of 4-12 VOCs in the 12 months prior to the screening period, with at least 2 during the last 6 months while on HU/HC. If receiving erythropoietin stimulating agent, the participant must have been receiving the drug for at least 6 months prior to screening visit and plan to continue taking the drug at the same dose and schedule until the participant has reached 52 weeks of the planned study treatment.
Participants who have not been receiving HU/HC, and/or erythropoietin stimulating agent must not have received it for at least 6 months prior to screening visit.
Key Exclusion Criteria:
- Fewer than 4 or more than 12 VOCs that are HCP-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) within the 12 months prior to screening visit as determined by medical history and documented at source.
- History of stem cell transplant and/or gene therapy.
- Received blood products within 30 days prior to Week 1 Day 1 dosing.
- Any documented history of a clinical stroke or intracranial hemorrhage, or an uninvestigated neurologic finding within the past 12 months before screening visit. Silent infarct only present on imaging is not excluded.
- Participating in a chronic transfusion program (pre-planned series of transfusions for prophylactic purposes) and/or planning to undergo an exchange transfusion during the duration of the study; episodic transfusion in response to worsened anemia or VOC is permitted.
- Contraindication or hypersensitivity to any drug or metabolites from similar class as study drug or to any excipients of the study drug formulation. History of severe hypersensitivity reaction to other monoclonal antibodies, which in the opinion of the investigator may pose an increased risk of serious infusion reaction.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Crizanlizumab (SEG101) at 5.0 mg/kg
Participants receive Crizanlizumab (SEG101) at 5.0 mg/kg and standard of care. |
Crizanlizumab is supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for IV infusion.
Autres noms:
|
|
Comparateur placebo: Placebo
Participants receive the placebo drug and standard of care. |
Placebo is supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for IV infusion. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Annualized rate of VOCs that are healthcare professional (HCP)-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) in each treatment arm
Délai: 1 year
|
Vaso oclusive crisis (VOC) is defined as a pain crisis (acute onset of pain for which there is no other medically determined explanation other than vaso-occlusion) lasting for at least 4 hours which is treated as per local guidelines with standard of care therapy used to treat VOC. Acute chest syndrome (ACS), priapism and hepatic or splenic sequestration will be considered VOC in this study. VOCs included are those HCP-managed in a healthcare facility and HCP-managed via remote consultation. Annualized rate of VOC events = (Number of VOC events * 365)/(number of days in the observation period). Observation period = time from date of randomization to minimum of (last dose date until treatment discontinuation + 27 days, date of initiation or discontinuation of HU/HC or L-Glutamine (or other therapies such as Voxelotor and erythropoietin therapies to treat SCD and/or to prevent/reduce VOCs), date of randomization + 365 days). |
1 year
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
The annualized rate of all VOCs including VOCs that are HCP-managed (either at a health care facility or via remote consultation) as well as those that are self-managed without recommendations from HCP during the event in each treatment arm
Délai: 1 year
|
VOCs can be categorized as those HCP-managed in a healthcare facility, HCP-managed via remote consultation, or self-managed without recommendations from HCP during the event. Annualized rate of VOC events = (Number of VOC events * 365)/(number of days in the observation period). To capture VOC events that are self-managed, and in order to avoid VOC recall bias and to make sure the pain events are captured in real-time, a cloud-based application will be used and setup an account for each participant. |
1 year
|
|
Annualized rate of VOC by subtype of management in each treatment arm over the planned 52-week period.
Délai: 1 year
|
Vaso oclusive crisis (VOC) is defined as a pain crisis lasting for at least 4 hours which is treated as per local guidelines with standard of care therapy. Acute chest syndrome (ACS), priapism and hepatic or splenic sequestration will be considered VOC in this study. VOCs can be categorized as those HCP-managed in a healthcare facility, HCP-managed via remote consultation, or self-managed without recommendations from HCP during the event. Annualized rate of VOC is the number of VOC events during a year period. |
1 year
|
|
The time to first VOC that is HCP-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) between treatment arms.
Délai: 1 year
|
VOC is defined as a pain crisis lasting for at least 4 hours which is treated as per local guidelines with standard of care therapy. ACS, priapism and hepatic or splenic sequestration will be considered VOC in this study. VOCs included are those HCP-managed in a healthcare facility and HCP-managed via remote consultation. Time to first occurrence of VOC that is HCP-managed (either at a health care facility or via remote consultation) is defined as the time from the date of randomization to the date of the first occurrence of the VOC. |
1 year
|
|
Proportion of participants free from VOCs that are HCP-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) in each treatment arm over the planned 52-week treatment period.
Délai: 1 year
|
To assess the number of participants free from VOCs leading to healthcare visit. VOC is defined as a pain crisis lasting for at least 4 hours which is treated as per local guidelines with standard of care therapy. ACS, priapism and hepatic or splenic sequestration will be considered VOC in this study. A participant is free from VOC if they do not have a VOC crisis. |
1 year
|
|
Duration of VOCs that are HCP-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) in each treatment arm over the planned 52-week treatment period.
Délai: 1 year
|
VOC is defined as a pain crisis lasting for at least 4 hours which is treated as per local guidelines with standard of care therapy. ACS, priapism and hepatic or splenic sequestration will be considered VOC in this study. Duration of HCP-managed VOC is defined as end date of the VOC - start date of the VOC + 1 day. |
1 year
|
|
Number of participants with anti-SEG101 (crizanlizumab) antibodies (any time)
Délai: 2 years
|
Immunogenicity: measurement of anti-drug antibodies (ADA) to crizanlizumab. |
2 years
|
|
Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Délai: 2 years
|
Incidence and severity of AEs and SAEs by treatment group, including changes in vital signs, electrocardiograms (ECGs), and laboratory results qualifying and reported as AEs. |
2 years
|
|
Absolute change from baseline in hemoglobin
Délai: Baseline, 2 years
|
Assessment of safety of SEG101 |
Baseline, 2 years
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies génétiques, innées
- Anémie, hémolytique, congénitale
- Anémie, hémolytique
- Anémie
- Hémoglobinopathies
- Maladies et anomalies congénitales, héréditaires et néonatales
- Maladies hémiques et lymphatiques
- Anémie, Drépanocytose
- Maladies hématologiques
- Trait drépanocytaire
- Crises vaso-occlusives
- crizanlizumab
Autres numéros d'identification d'étude
- CSEG101A2303
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .